NO for preterm infants at risk of bronchopulmonary dysplasia

Mercier and colleagues might have enrolled infants with such mild disease (about 10% of babies required continuous positive airway pressure only at randomisation) that the potential benefit of inhaled nitric oxide might have been minimised by excluding the infants at high risk of developing bronchop...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2010-07, Vol.376 (9738), p.308-310
Hauptverfasser:	Sosenko, Ilene RS, Bancalari, Eduardo
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Age Factors Angiogenesis Babies Bronchopulmonary Dysplasia - drug therapy Bronchopulmonary Dysplasia - prevention & control Clinical trials Clinical Trials as Topic Drug Administration Schedule European Union Free Radical Scavengers - administration & dosage Humans Illnesses Infant, Newborn Infant, Premature Infants Internal Medicine Lungs Multicenter Studies as Topic Nitric oxide Nitric Oxide - administration & dosage Randomized Controlled Trials as Topic Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Mercier and colleagues might have enrolled infants with such mild disease (about 10% of babies required continuous positive airway pressure only at randomisation) that the potential benefit of inhaled nitric oxide might have been minimised by excluding the infants at high risk of developing bronchopulmonary dysplasia.
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(10)61051-3